Allergan PLC (AGN)

NYSE
193.02
0.00(0.00%)
  • Volume:
    0
  • Day's Range:
    191.64 - 193.38
  • 52 wk Range:
    0.00 - 0.00

AGN Overview

Prev. Close
192.99
Day's Range
191.64-193.38
Revenue
16.1B
Open
193.01
52 wk Range
0-0
EPS
-7.59
Volume
0
Market Cap
63.65B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
3,077,701
P/E Ratio
-
Beta
1.16
1-Year Change
0%
Shares Outstanding
329,805,791
Next Earnings Date
-
What is your sentiment on Allergan?
or
Market is currently closed. Voting is open during market hours.

Allergan PLC News

Allergan PLC Analysis

Allergan PLC Company Profile

Allergan PLC Company Profile

Employees
17400

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, central nervous system, women’s health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; In addition, it develops medical and cosmetic treatments; treatments for neurodegenerative disorders; and inflammatory and fibrotic diseases. It has a collaboration, option, and license agreement with Lyndra, Inc. to develop orally administered products for the treatment of Alzheimer’s disease; strategic alliance and option agreement with Editas Medicine, Inc.; and Allergan plc also has licensing agreements with Assembly Biosciences, Inc. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was incorporated in 2013 and is headquartered in Dublin, Ireland. As of May 8, 2020, Allergan plc operates as a subsidiary of AbbVie Inc.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuySellStrong BuyStrong Buy
SummaryStrong BuyStrong BuyNeutralStrong BuyStrong Buy
  • I have been watching this since before the merger news broke. and the way it has been acting and the large "dark pool" orders and the fat fingers down its acting the same way...there will be more news soon. idk what it may be another company with a bigger offer or something...I know theyll probably beat eps. and they have declared a .74 cent dividend . they also have new drugs available in the US and new trials starting . would not be surprised to see another buyout off of 200 ps or even higher.
    2
    • I would be very surprised if another buyout offer came in. As for anti-trust issues, I don't see that either. No overlapping drugs. The Democrats that want to block the merger, just dislike pharma company's and this merger is a way for some of the presidential candidates to get some airtime and try to convince Ameticans this merger is a way for bug pharma to get more leverage, when all it really is, is a cost savings initiative to combine and eliminate some duplication.
      0
  • news will come soon of a potential better offer. price is acting same as it was before...just wait ...
    1
    • Really, really odd that this is down. There must be doubts about this going through.
      0
      • Shooting to 188$
        1
        • Not sure another bidder will come to the table. If PFE hadn't just paid cash for ARRY, they might have come to the party here.
          0
        • oh yea put some more of my out of the money call options $30 in the money!!!
          1
      • AGN $164.00 +26.57%
        0
        • 170$
          0
          • Actually will get to 188 since that is the selling price. not sure why you're hung on 170.
            0
          • John Perry The deal is not for sure! It is scheduled for early 2020. So many of these deals do not happen. You should read the buyout more carefully. It states a 120 per share with a .81 ABBV per share add. .81 * ABBV current price per share 67.8 = 174.91. That is your best case scenario. What happens when ABBV drops to $50 before the deal. Now your looking at $160 a share.
            0
        • Triangle?
          0
          • Law suits are coming on their breast implants that have caused cancer
            1
            • Potential buyout candidate. But probably not worth the downside risk.
              0
              • $143
                0